JPRN-UMIN000023560未知未知
A feasibility study of TS-1 and oxaliplatin for Stage III gastric cancer in adjuvant setting - A feasibility study of TS-1 and oxaliplatin for gastric cancer
Department of Surgical Oncology, Osaka City University Graduate School of Medicine0 个研究点目标入组 40 人开始时间: 2017年8月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. With synchronous or metachronous (within 5 year before entry) double cancer, except for situ carcinoma 2. Severe surgical complication 3. Severe complication; such as uncontrollable diabetes mellitus or hypertension 4.With Peripheral sensory neuropathy 5. Active infectious disease 6. Positive for HBs antigen or HCV antibody 7. Continuous administration of steroids 8. Severe diarrhea 9. With drug allergy for both of iodine and gadolinium 10. Continuous flucytosine, phenytoin, and warfarin potassium treatment 11. Women during pregnancy, possible pregnancy, or breast-feeding and men with making pregnant 12. Cases judged to be inappropriate by attending physician
研究者
相似试验
招募中
1 期
Phase I/II Study of TS-1/Oxaliplatin(SOX) for patients with unresectable advanced or recurrent gastric cancerunresectable advanced or recurrent gastric cancerJPRN-UMIN000015807Gunma University Graduate School of Medicine72
已完成
不适用
The feasibility study of TAS-118 plus Oxaliplatin or TAS-118 monotherapy as perioperative chemotherapy for locally advanced gastric cancerResectable gastric cancerJPRN-UMIN000024688The Cancer Institute Hospital of JFCR45
招募中
2 期
Phase II study of TS-1 / oxaliplatin(G-SOX) plus bevacizumab treatment for elderly advanced colorectal cancer patients.(GIANTS study)colorectal cancerJPRN-UMIN000009014niversity of Miyazaki Hospital.50
已完成
1 期
Combination chemotherapy of TS-1, oxaliplatin and irinotecan (TIROX) for unresectable gastric cancer; a phase I studygastric cancerJPRN-UMIN000030482Osaka Medical College Hospital18
已完成
2 期
A multicenter phase II trial of TS-1+oxaliplatin+panitumumab as first-line treatment in patients with kras-wild type unresectable advanced colorectal liver metastasis.colorectal cancerJPRN-UMIN000007236Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences2